Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There was 0 good news.
The only surprises were on downside. Revenues and cash. Why would the stock go up? If pphm is going to run like a manufacturing company, promise profitability, they can't miss revenues like that. They would need much more discipline than they have demonstrated to operate a profitable group that met their sales, cash, profit, dso, etc. numbers.
Nah, like I said SK speaks and the $.3x's return. The Lid is a fiction of people's imagination. The market for pphm these days is; day-traders, bottom feeders, boiler rooms, pphm, and perhaps some institutions trying to get out.
Yes the deferred revenue will move from a liability on balance sheet, to the income statement as the client work is performed and invoiced. It represents income for which they have not performed work for or whose collection is dubious or otherwise can not meet the standard for income recognition. The deferred liability is offset by the cash increase on balance sheet.
If you have the goods you don't need to pay people to test your goo. Perhaps you do this tactically to augment other trials or philanthropically, but if this is your only path to fda approval, something is very wrong.
So now the best value proposition that can be made for pphm is that, "they lost so much money someone will acquire for the credits?" I can see the bp's head of acquisitions pitching that to executives now. "We really should buy pphm they are so great at loosing money we can benefit" btw were there any questions on Bavi for crops?
Yes only the smallest of mom and pop operations account for their company on a cash basis - and they shouldn't. I suppose if you receive all of your income as cash (no receivables) and pay everyone in cash (no payables) it could make sense but who operates like that. Accrual accounting is the only way to budget, forecast and run a business.
Soft assets are a common term not sure the context of the post but it is not a made up thing Soft assets = intangible assets/goodwill
50 day is 812,166 I rounded down to account for yesterday.
Back to the $.30's once SK starts talking.
I agree money well spent. Much better than giving it to SK and BOD, but it is not some huge industry endorsement. It is not a bp putting skin in the game. It is another fishing trip.
Actually average volume was more like 700k and the big volume day was a whopping $2m. Looks like the big boys got in with both fists, don't you think.
No matter how you spin it PPHM gave NCCN a $2m grant. pphm pays NCCN
5 million shares is only ~$2m of turnover. This is hardly volume that starts a trend change. Not to mention the overhead of ATM and the pending RS.
Nah no way they take pphm $$ unless it is a guaranteed moonshot. You make it sound like NCCN is investing their money. Sure pphm has to have interesting science. That hardly is a guarantee of commercial success - as pphm has proven
No one is saying it is a bad idea. But certainly not a major coup or credibility builder. And this is deja vous all over again. They announced long ago that they were "planning trials with NCCN". After all this time now what do they announce, we are "planning trials with NCCN".
Do you understand that bavi is a total failure in chemo settings and no data coming anytime soon for ANY indication? That pphm mgmt has 0 credibility in the industry at this point. That the bod is considered by any honest investor to be self-dealing and not acting in shareholder's best interest?
The work of conspiracy theorists. No one is being paid to bash pphm. There is just not enough $$ to be bothered with by "pros" as your repost suggests. pphm is a broken penny stock - simple as that.
The shorting data you are looking at is primarily intraday mm shorting to maintain the book for the day.
lol.
$50m is a tiny company. Of course CEO of a typical $50m bio mfg makes less than SK
If the choice is RS or eaving Nasdaq and drying up the source of funds, thus forcing a reorg, that would be a better thing. This is all such a shame for shareholders. It would be relatively easy to get the shareprice above $1.
1- SK goes - It's time.
2 - BOD adds a seasoned bio vet and announces they are seeking a new ceo from the industry ready to partner
3 - Company is reorged with substantial dead weight in upper management gone
4 - AVID is spun out, setup for success and get's future capital needs like every other manufacturing concern.
Clearly this is in shareholders interest but not bod and management.
Must be accumulation by a bp poised to swoop in and acquire.
And wouldn't it be nice if sr mgmt was staffed and paid like a mfg. company.
Yes it is amazing that anyone could both support the company and bod AND want to write letters to SEC in hopes they generate a company probe.